Evidence map›Paper›PMID 26937021›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2016

Identification of Tazarotenic Acid as the First Xenobiotic Substrate of Human Retinoic Acid Hydroxylase CYP26A1 and CYP26B1.

Robert S Foti, Nina Isoherranen, Alex Zelter, Leslie J Dickmann, Brian R Buttrick, Philippe Diaz, Dominique Douguet

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Robert S FotiAmgen Pharmacokinetics and Drug Metabolism, Seattle, Washington (R.S.F.); Department of Pharmaceutics, University of Washington, Seattle, Washington (N.I., A.Z., L.J.D., B.R.B.); Core Laboratory for Neuromolecular Production, Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana (P.D.); CNRS, Université Nice Sophia Antipolis, Institut de Pharmacologie Moléculaire et Cellulaire, UMR 7275, Valbonne, France (D.D.) rfoti@amgen.com.
Nina IsoherranenAmgen Pharmacokinetics and Drug Metabolism, Seattle, Washington (R.S.F.); Department of Pharmaceutics, University of Washington, Seattle, Washington (N.I., A.Z., L.J.D., B.R.B.); Core Laboratory for Neuromolecular Production, Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana (P.D.); CNRS, Université Nice Sophia Antipolis, Institut de Pharmacologie Moléculaire et Cellulaire, UMR 7275, Valbonne, France (D.D.).
Alex ZelterAmgen Pharmacokinetics and Drug Metabolism, Seattle, Washington (R.S.F.); Department of Pharmaceutics, University of Washington, Seattle, Washington (N.I., A.Z., L.J.D., B.R.B.); Core Laboratory for Neuromolecular Production, Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana (P.D.); CNRS, Université Nice Sophia Antipolis, Institut de Pharmacologie Moléculaire et Cellulaire, UMR 7275, Valbonne, France (D.D.).
Leslie J DickmannAmgen Pharmacokinetics and Drug Metabolism, Seattle, Washington (R.S.F.); Department of Pharmaceutics, University of Washington, Seattle, Washington (N.I., A.Z., L.J.D., B.R.B.); Core Laboratory for Neuromolecular Production, Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana (P.D.); CNRS, Université Nice Sophia Antipolis, Institut de Pharmacologie Moléculaire et Cellulaire, UMR 7275, Valbonne, France (D.D.).
Brian R ButtrickAmgen Pharmacokinetics and Drug Metabolism, Seattle, Washington (R.S.F.); Department of Pharmaceutics, University of Washington, Seattle, Washington (N.I., A.Z., L.J.D., B.R.B.); Core Laboratory for Neuromolecular Production, Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana (P.D.); CNRS, Université Nice Sophia Antipolis, Institut de Pharmacologie Moléculaire et Cellulaire, UMR 7275, Valbonne, France (D.D.).
Philippe DiazAmgen Pharmacokinetics and Drug Metabolism, Seattle, Washington (R.S.F.); Department of Pharmaceutics, University of Washington, Seattle, Washington (N.I., A.Z., L.J.D., B.R.B.); Core Laboratory for Neuromolecular Production, Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana (P.D.); CNRS, Université Nice Sophia Antipolis, Institut de Pharmacologie Moléculaire et Cellulaire, UMR 7275, Valbonne, France (D.D.).
Dominique DouguetAmgen Pharmacokinetics and Drug Metabolism, Seattle, Washington (R.S.F.); Department of Pharmaceutics, University of Washington, Seattle, Washington (N.I., A.Z., L.J.D., B.R.B.); Core Laboratory for Neuromolecular Production, Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana (P.D.); CNRS, Université Nice Sophia Antipolis, Institut de Pharmacologie Moléculaire et Cellulaire, UMR 7275, Valbonne, France (D.D.).
University of Montana · USCentre National de la Recherche Scientifique · FRAmgen (United States) · USUniversity of Washington · US

Funding

Mechanisms of Regulation of Retinoic Acid HomeostasisR01GM111772 · NIGMS · UNIVERSITY OF WASHINGTON · PI ISOHERRANEN, NINA · 2014 to 2021
$3.0M
Effects of Xenobiotics on CYP26 Activity and Retinoic Acid HomeostasisR01GM081569 · NIGMS · UNIVERSITY OF WASHINGTON · PI ISOHERRANEN, NINA · 2008 to 2012
$1.7M
Inhibition of retinoic acid metabolism for reversal of cognitive deficits in ADR41AG046987 · NIA · DERMAXON, LLC · PI ASTRUC DIAZ, FANNY · 2013 to 2013
$225k
NIA NIH HHS R41 AG046987NIA NIH HHS R41AG046987NIGMS NIH HHS R01 GM081569NIGMS NIH HHS R01-GM081569NIGMS NIH HHS R01 GM111772NIGMS NIH HHS R01-GM111772
6 · The paper itself

Abstract

Cytochrome P450 (CYP) 26A1 and 26B1 are heme-containing enzymes responsible for metabolizing all-trans retinoic acid (at-RA). No crystal structures have been solved, and therefore homology models that provide structural information are extremely valuable for the development of inhibitors of cytochrome P450 family 26 (CYP26). The objectives of this study were to use homology models of CYP26A1 and CYP26B1 to characterize substrate binding characteristics, to compare structural aspects of their active sites, and to support the role of CYP26 in the metabolism of xenobiotics. Each model was verified by dockingat-RA in the active site and comparing the results to known metabolic profiles ofat-RA. The models were then used to predict the metabolic sites of tazarotenic acid with results verified by in vitro metabolite identification experiments. The CYP26A1 and CYP26B1 homology models predicted that the benzothiopyranyl moiety of tazarotenic acid would be oriented toward the heme of each enzyme and suggested that tazarotenic acid would be a substrate of CYP26A1 and CYP26B1. Metabolite identification experiments indicated that CYP26A1 and CYP26B1 oxidatively metabolized tazarotenic acid on the predicted moiety, with in vitro rates of metabolite formation by CYP26A1 and CYP26B1 being the highest across a panel of enzymes. Molecular analysis of the active sites estimated the active-site volumes of CYP26A1 and CYP26B1 to be 918 Å(3)and 977 Å(3), respectively. Overall, the homology models presented herein describe the enzyme characteristics leading to the metabolism of tazarotenic acid by CYP26A1 and CYP26B1 and support a potential role for the CYP26 enzymes in the metabolism of xenobiotics.

Indexed as

Amino Acid SequenceCatalytic DomainCytochrome P-450 Enzyme SystemHumansKineticsModels, MolecularMolecular Sequence DataNicotinic AcidsPharmaceutical PreparationsReceptors, Retinoic AcidRetinoic Acid 4-HydroxylaseSubstrate SpecificityTretinoinXenobioticsCYP26B1 protein, humanCytochrome P-450 Enzyme SystemNicotinic AcidsPharmaceutical PreparationsReceptors, Retinoic AcidRetinoic Acid 4-Hydroxylasetazarotenic acidTretinoinXenobiotics

Identifiers

PMID26937021
PMCPMC4851321
OpenAlexW2292837418

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.